Valion Bio, Inc. · NASDAQ:VBIO
Valion Bio — Tivic Health Systems — Investor Presentation (May 2024)
19 slides from Valion Bio's investor presentation, May 22, 2024
Slide 1: The future of medicine is electronic
NASDAQ TIVC INVESTOR PRESENTATION 2022 SEPT The future of medicine is electronic. NASDAQ : TIVC INVESTOR PRESENTATION May 2024
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation may be forward-looking statements. Statements regarding our future results of operations and financial position, economic performa
Slide 3: Investment Highlights
References provided in Appendix . Investment Highlights TIVIC HEALTH Commercial-stage in Bioelectronic Medicine, field projected to grow at 35% CAGR 2019-20291 One of the most promising new fields of medicine. FDA-approved product in market targeting $9.1B addressable market2 First product (ClearUP)
Slide 4: The Big Idea: Bioelectronic Medicine
THE BIG IDEA: BIOELECTRONIC MEDICINE The body is an electrochemical system. Restore healthy function by engaging the body’s electrical signals. Bioelectronic medicine represents a multi-billion-dollar opportunity and has the “potential to become a pillar of medical treatment.” Bioelectronics ‘jump-s
Slide 5: Tivic Business Snapshot
FDA Approved to clear congestion, stop sinus pain $249 MSRP 5 minutes, 2x per day Bioelectronic Platforms Regulatory Approvals Peer-reviewed Publications AND TIER 1 COLLABORATORS FOR CLEARUP PRODUCT 2 Product in Market 1 Trigeminal and Sympathetic Nerves Signed New Distribution Agreements 2023 Prefe
Slide 6: Tivic Specializes in Non-invasive Nerve Stimulation
TIVIC SPECIALIZES IN Non-invasive Nerve Stimulation GUIDED HANDHELD NEUROMODULATION (COMMERCIAL) Trigeminal nerve mediates pain signals1,2; Sympathetic nerves regulate vasoconstriction3-7 Detects subcutaneous structures; guides user to optimal treatment points Sold under ClearUP brand, white-labelin
Slide 7: Core Technology: Bioelectronic Platform
CORE TECHNOLOGY BIOELECTRONIC “PLATFORM” Programmable Signal Parameters Patented Electrical and Industrial Designs Proprietary Algorithms Tivic has unique expertise to optimize the delivery of effective, low-current, non-invasive neuromodulation 7
Slide 8: Tivic's Strategy to Increase Value
Leveraging core competencies in new high-value target TIVIC’S STRATEGY TO INCREASE VALUE Vagus nerve is a high-value target for medical applications. Connects all major organs. Regulates autonomic nervous system. Effects on cardiac, neurological and immune systems.1 Implanted vagus nerve stimulators
Slide 9: VNS Landscape
Significant whitespace in medical-grade, non-invasive VNS therapeutic devices VNS LANDSCAPE Non-invasive “Wellness” VNS Not rigorously tested, not optimized Not subject to FDA oversight No clinical validation required (not “evidence based”) Low valuations Marketed for Stress1 Marketed for Stress1 Ma
Slide 10: Tivic's ncVNS Study
Sophisticated testing and measurement of VNS response TIVIC’S ncVNS STUDY Non-invasive Cervical Vagus Nerve Stimulation (ncVNS) N = 20 Healthy Subjects One-time stimulation, 20 minutes Novel current delivery methods and proprietary simulation parameters Physiologic Outcome Measures Pupillometry (Pup
Slide 11: Topline ncVNS Study Outcomes: Pupil Constriction
Sustained pupil constriction during stimulation TIVIC TOPLINE ncVNS STUDY OUTCOMES Pupil constriction indicates increased parasympathetic tone1 9.5% reduction in pupil diameter Indicates vagus nerve has been engaged Before During Clinical Testing conducted by The Institute for Bioelectronic Medicine
Slide 12: Topline ncVNS Study Outcomes: RMSSD Increase
Large, clinically meaningful increase in RMSSD – a measure of heart rate variability, vagal tone and parasympathetic activity TIVIC TOPLINE ncVNS STUDY OUTCOMES Importance of RMSSD RMSSD is an accepted proxy for vagal tone and parasympathetic activity1 Increasing parasympathetic activity may treat o
Slide 13: Topline ncVNS Study Outcomes: Brain Activity
Large, clinically meaningful changes in brain activity TIVIC TOPLINE ncVNS STUDY OUTCOMES Theta Activity: Increased frontal theta activity expected to be useful in treating anxiety, PTSD and other psychiatric disorders1 24% increase in frontal theta activity – associated with calm awake states, lear
Slide 14: Why this matters
Why this matters Our topline ncVNS data indicate large rapid effects in clinically important biological measures (cardiac, brain, autonomic). Implanted technologies have validated clinical efficacy and commercial viability of VNS but are not always appropriate for the clinical scenario.1 Non-invasiv
Slide 15: Catalyst-rich period for Tivic
cv Catalyst-rich period for Tivic ACCELERATING VALUE CREATION NEAR TERM 12 MONTHS + COMPLETED Clinical Engineering Commercial Proof of Concept Concept demonstrated Phase I Safety validated in healthy subjects Effect size baseline established Enrollment complete Data analysis in progress Successful P
Slide 16: Experienced, Execution-oriented Team
Experienced, Execution-oriented Team LEADERSHIP TEAM Jennifer Ernst Chief Executive Officer, MBA Founded company in 2016, built Tivic Health from founding to IPO in 5 years; first medical product in market in 3 years. Took prior company (Thin Film Electronics ASA) from 8-person R&D company to $480MM
Slide 17: Investment Highlights
. Investment Highlights TIVIC HEALTH Commercial-stage in Bioelectronic Medicine, field projected to grow at 35% CAGR 2019-20291 One of the most promising new fields of medicine. FDA-approved product in market targeting $9.1B addressable market2 First product (ClearUP) targets inflammation of sinus p
Slide 18: Jennifer Ernst, CEO, Tivic Health
Jennifer Ernst CEO, Tivic Health jennifer.ernst@tivichealth.com
Slide 19: Appendix: Footnotes
APPENDIX: FOOTNOTES NON-INVASIVE NERVE STIMULATION Wilson-Pauwels, L., Akesson, E. J., Stewart, P. A. Cranial Nerves: Anatomy and Clinical Comments. B. C. Decker, 1998. Maul, Ximena A., et al. "Microcurrent technology for rapid relief of sinus pain: a randomized, placebo‐controlled, double‐blinded c
Tivic Health Systems — Investor Presentation (May 2024) on 6ix